Back to news

Hims & Hers Health gains as Germany launch adds to expansion momentum

Investivoq PriceTracker

Hims & Hers Health (HIMS) is up 5.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely catalyst is the company’s October 20 launch of Hims in Germany, which expands its weight-management offering into another large international market. The move also appears to fit a broader growth narrative around overseas expansion and investor positioning ahead of the company’s next quarterly results.

Details:

  • The company announced on October 20 that Hims has launched in Germany, starting with men’s weight-management care.
  • The rollout is aimed at a market where the company highlighted high rates of overweight and obesity, suggesting a meaningful addressable customer base.
  • The launch follows other recent international expansion steps, including leadership additions for the UK, EMEA, and Australia, reinforcing that overseas growth remains a strategic priority.
  • This could also be because traders are looking ahead to third-quarter 2026 results scheduled for November 9, which can support momentum in faster-growing health platform names.

    • Sources:

    Hims & Hers Newsroom, Hims & Hers Investor Relations, SEC

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $HIMS Insider Trading Activity

    HIMS Insider Trades

    $HIMS insiders have traded $HIMS stock on the open market 24 times in the past 6 months. Of those trades, 1 have been purchases and 23 have been sales.

    Here’s a breakdown of recent trading of $HIMS stock by insiders over the last 6 months:

    • OLUYEMI OKUPE (Chief Financial Officer) has made 0 purchases and 10 sales selling 153,772 shares for an estimated $4,942,061.
    • DAVID B WELLS purchased 48,400 shares for an estimated $1,172,974
    • MOHAMED ELSHENAWY (CTO) has made 0 purchases and 2 sales selling 37,994 shares for an estimated $1,172,074.
    • SOLEIL BOUGHTON (Chief Legal Officer) has made 0 purchases and 5 sales selling 41,727 shares for an estimated $1,165,042.
    • MICHAEL CHI (Chief Operating Officer) has made 0 purchases and 2 sales selling 28,054 shares for an estimated $840,077.
    • PATRICK HARRISON CARROLL (Chief Medical Officer) sold 23,726 shares for an estimated $830,410
    • DEBORAH M. AUTOR (Chief Policy Officer) sold 16,773 shares for an estimated $467,128
    • IRENE BECKLUND (PAO) has made 0 purchases and 2 sales selling 12,063 shares for an estimated $370,518.

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    EARLY ACCESS
    Receive HIMS Data Alerts
    Real-time alerts on filings, insider trades, and market signals — before everyone else.
    Get Alerts →

    $HIMS Hedge Fund Activity

    We have seen 291 institutional investors add shares of $HIMS stock to their portfolio, and 205 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • DEFIANCE ETFS, LLC removed 7,424,258 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $257,399,024
    • DIVISADERO STREET CAPITAL MANAGEMENT, LP added 5,539,672 shares (+1179.1%) to their portfolio in Q2 2026, for an estimated $192,060,428
    • JPMORGAN CHASE & CO added 4,766,781 shares (+inf%) to their portfolio in Q2 2026, for an estimated $165,264,297
    • FMR LLC added 4,230,022 shares (+4535.2%) to their portfolio in Q2 2026, for an estimated $146,654,862
    • MARSHALL WACE, LLP added 3,493,540 shares (+482.4%) to their portfolio in Q2 2026, for an estimated $121,121,031
    • GOLDMAN SACHS GROUP INC added 2,719,170 shares (+110.8%) to their portfolio in Q2 2026, for an estimated $94,273,623
    • SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 2,453,787 shares (+inf%) to their portfolio in Q2 2026, for an estimated $85,072,795

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $HIMS Price Targets

    Multiple analysts have issued price targets for $HIMS recently. We have seen 7 analysts offer price targets for $HIMS in the last 6 months, with a median target of $35.0.

    Here are some recent targets:

    • Allen Lutz from B of A Securities set a target price of $37.0 on 07/09/2026
    • Maria Ripps from Canaccord Genuity set a target price of $40.0 on 07/01/2026
    • Glen Santangelo from Barclays set a target price of $39.0 on 06/18/2026
    • Jailendra Singh from Truist Securities set a target price of $23.0 on 05/22/2026
    • Ryan MacDonald from Needham set a target price of $35.0 on 05/12/2026
    • Cory Carpenter from JP Morgan set a target price of $33.0 on 05/12/2026
    • Daniel Grosslight from Citigroup set a target price of $28.0 on 05/12/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.